排序方式: 共有82条查询结果,搜索用时 15 毫秒
71.
目的评价替吉奥联合塞来昔布治疗晚期胃癌的疗效、不良反应,以及其对血管内皮生长因子(VEGF)和免疫功能的影响。方法 93例晚期胃癌患者随机分为2组,观察组48例接受替吉奥联合塞来昔布治疗,对照组45例接受单药替吉奥治疗。比较2组患者疗效、不良反应、VEGF水平及免疫功能。结果观察组和对照组患者治疗有效率分别为29.2%和26.7%,2组比较差异无统计学意义(P>0.05)。观察组患者疾病控制率(81.3%)显著高于对照组(68.9%)(P<0.05)。观察组患者临床受益率(83.3%)显著高于对照组(55.6%)(P<0.05)。2组患者常见不良反应为骨髓抑制、恶心和呕吐、腹泻、乏力、色素沉着、皮疹等,多为Ⅰ~Ⅱ级,不良反应发生率比较差异无统计学意义(P>0.05)。观察组患者化学治疗后VEGF水平治疗前和对照组治疗后(P<0.05)。2组患者化学治疗后CD3+、CD4+、CD4+/CD8+水平均较化学治疗前显著升高(P<0.05),且化学治疗后观察组患者显著高于对照组(P<0.05)。结论替吉奥联合塞来昔布治疗晚期胃癌安全、有效,并可改善患者机体免疫功能,且患者耐受性良好。 相似文献
72.
目的:分析和评估一款热塑膜固定底板对调强放射治疗(IMRT)计划三维剂量验证通过率的影响,并对其进行剂量修正。方法:利用Octavius 4D三维剂量验证系统,对60例IMRT计划按照后入射野数占总射野数比值分成6组,分别进行仅有床板和有床板与热塑膜固定底板组合的三维剂量验证,以评估热塑膜固定底板对IMRT三维剂量验证通过率的影响。然后对入射野数占比最大的第6组进行剂量修正,并与修正前的γ通过率进行比较,评估剂量修正的作用。结果:未考虑固定底板时,6组IMRT计划γ通过率分别为:98.00%、96.87%、96.76%、94.82%、95.51%、95.32%;考虑固定底板以后分别为:98.88%、96.46%、95.85%、93.12%、93.22%、89.07%,考虑前后P值分别为0.147、0.534、0.406、0.051、0.030(t=2.566)、0.000(t=5.637),第5组和第6组有统计学差异。对第6组进行固定底板剂量修正以后,γ通过率平均为94.90%,提高5.8%。结论:热塑膜固定底板对IMRT计划三维剂量验证通过率有一定的影响,且当IMRT计划的后入射野数所占总射野数比值越大,影响越大,临床制定计划时有必要对固定底板进行剂量修正。 相似文献
73.
放射线可引起细胞 DNA 损伤,导致肿瘤细胞周期阻滞,并引导细胞凋亡.野生型p53(WTp53)可使细胞阻滞于G2/M期,产生凋亡和细胞增殖抑制作用,而有利于发挥放疗敏感性,因此基因的改变尤其是抑癌基因p53对放疗的疗效起决定性的调控作用.而p53基因的变异(MTp53)将失去这种功能,这是产生肿瘤细胞放射抵抗的重要原因之一 [1]. 相似文献
74.
75.
单药每周紫杉醇同步放疗治疗中晚期老年或低生活状态食管癌42例临床观察 总被引:1,自引:0,他引:1
目的观察单药紫杉醇每周方案同步放疗治疗中晚期老年或低生活状态食管癌疗效及毒副作用。方法病理确诊中晚期食管癌患者42例,老年36例,低生活状态(KPS评分〈70分并〉50分)6例,随机分为两组:单放组21例:常规分割放疗,1.8~2.0Gy/次,5次/周,总剂量60~70Gy/67周;放疗化疗同步组(综合组)21例,每周40mg/m^2紫杉醇同时联合常规分割放疗。结果单放组有效率(RR)71.4%,完全缓解(CR)33.3%,部分缓解(PR)38.1%;综合组RR85.7%,CR47.6%、PR38.1%(P〉0.05)。中位生存时间(MST)两组分别为9.2个月和12.8个月,1、2年生存率两组分别为66.7%、80.9%和47.6%、57.1%,但差异均无显著性(P〉0.05)。主要毒副作用为骨髓抑制、放射性食管炎,主要发生在综合组,患者均能耐受。低生活状态6例生活质量均有不同程度改善。结论单药紫杉醇每周方案同时结合放疗对中晚期老年或低生活状态食管癌安全、有效且可耐受,但有待于扩大样本量进一步研究。 相似文献
76.
77.
Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer 下载免费PDF全文
Objective: To explore the effect and mechanism of ginsenoside Rg3 (Shenyi Capsule, 参一胶囊) on the postoperative life span of patients with non-small cell lung cancer (NSCLC). Methods: The prospective, randomized, controlled method was adopted. One hundred and thirty- three patients with NSCLC were randomly assigned to 3 groups: Shenyi Capsule group (43 cases), combined therapy group (Shenyi Capsule plus chemotherapy, 46 cases), and chemotherapy group (44 cases). The survival rates, immune function and the correlation between vascular endothelial growth factor (VEGF) expression and clinical effect were analyzed in the three groups. Results: (1) The 1-year survival rate in the Shenyi group, the combined group and the chemotherapy group was 76.7% (33/43), 82.6% (38/46), and 79.5% (35/44), respectively; the 2-year survival rate was 67.4% (29/43), 71.7% (33/46), and 70.5% (31/44), respectively; and the 3-year survival rate was 46.5% (20/43), 54.3% (25/46), and 47.7% (21/44), respectively. There was no significant difference among the 3 groups (P〉0.05). (2) NK cells were increased to different degrees and the ratio of CD4/CD8 was normal in the Shenyi Capsule group and the combined group, while the ratio of CD4/CD8 was disproportional in the chemotherapy group. (3) In the chemotherapy group, the 3-year survival rate was lower in patients with positive expression of VEGF than in patients with negative expression (37.0% vs 64.7%, χ^2=17.9, P〈0.01), but no significant statistical difference was shown in the other two groups (53.6% vs 55.6%, P〉0.05; 44.4% vs 50.0%, P〉0.05). Conclusion: Shenyi Capsule, especially in combination with chemotherapy, can improve the life span of patients with NSCLC after operation. The mechanism might be correlated with improving the immune function and anti-tumor angiogenesis. 相似文献
78.
79.
目的 研究TNF-α单核苷酸多态性与食管癌发生、发展和转移的关系.方法 以PCR-RFL方法分析了食管癌病例(n=202)和按性别、年龄频数对照的正常对照者(n=317)TNF-α-308G/A多态,并比较不同基因型与食管癌发生风险、分化程度以及淋巴结转移的关系.结果 TNF-α-308G/A基因频率在病例组与对照组中的分布无显著性差异(p>0.05),与食管癌发生风险无关.携带有A(G/A or A/A)等位基因的食管癌患者,其肿瘤恶性程度显著高于G/G基因型(79.8%&56.1%;OR=2.948,95%CI=1.468~5.920;P<0.05),而且,发生淋巴结转移的风险性显著增加(54.0% &34.5%:OR=2.223,95%CI=1.212~4.076;p<0.05).结论 TNF-α-308G/A多态性可能在食管癌的发展和转移中起一定作用. 相似文献
80.